PositiveID (PositiveID) Total Assets : $1.21 Mil (As of Mar. 2018)

View and export this data going back to 2007. Start your Free Trial

What is PositiveID Total Assets?

PositiveID's Total Assets for the quarter that ended in Mar. 2018 was $1.21 Mil.

Total Assets is connected with ROA %. PositiveID's annualized ROA % for the quarter that ended in Mar. 2018 was -778.22%. Total Assets is also linked to Revenue through Asset Turnover. PositiveID's Asset Turnover for the quarter that ended in Mar. 2018 was 0.29.

PositiveID Total Assets Historical Data

The historical data trend for PositiveID's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID Total Assets Chart

PositiveID Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Assets

Get a 7-Day Free Trial

1.40

1.02

4.70

2.56

1.73

PositiveID Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Total Assets	Get a 7-Day Free Trial															2.63	3.03	2.38	1.73	1.21

PositiveID Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PositiveID's Total Assets for the fiscal year that ended in Dec. 2017 is calculated as

Total Assets	=	Total Equity (A: Dec. 2017 )	+	Total Liabilities (A: Dec. 2017 )
	=	-9.701	+	11.426
	=	1.73

PositiveID's Total Assets for the quarter that ended in Mar. 2018 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2018 )	+	Total Liabilities (Q: Mar. 2018 )
	=	-10.709	+	11.922
	=	1.21

PositiveID (OTCPK:PSID) Total Assets Explanation

Total Assets is connected with ROA %.

PositiveID's annualized ROA % for the quarter that ended in Mar. 2018 is

ROA %	=	Net Income (Q: Mar. 2018 )	/	( (Total Assets (Q: Dec. 2017 )	+	Total Assets (Q: Mar. 2018 ))	/ count )
	=	-11.432	/	( (1.725	+	1.213)	/ 2 )
	=	-11.432	/	1.469
	=	-778.22 %

Note: The Net Income data used here is four times the quarterly (Mar. 2018) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PositiveID's Asset Turnover for the quarter that ended in Mar. 2018 is

	Asset Turnover
=	Revenue (Q: Mar. 2018 )	/	( (Total Assets (Q: Dec. 2017 )	+	Total Assets (Q: Mar. 2018 ))	/ count )
=	0.42	/	( (1.725	+	1.213)	/ 2 )
=	0.42	/	1.469
=	0.29

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PositiveID Total Assets Related Terms

Thank you for viewing the detailed overview of PositiveID's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PositiveID (PositiveID) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445

Website

http://www.psidcorp.com

PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.

Executives

Ned L Siegel	director	600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz	director	1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein	director	1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman	other: Former 10% Owner
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K	director	2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105